Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know
Atabak exercised options and immediately liquidated shares under a pre-established Rule 10b5-1 trading plan adopted in December 2025.
Overview
Chief Financial Officer Mokari Atabak reported the sale of 40,000 shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) on July 15, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($87.71); post-transaction value based on July 15, 2026 market close ($89.57).
Details
Corcept Therapeutics is a specialized pharmaceutical company with a market capitalization of $9.6 billion, generating TTM revenues of $769.1 million and demonstrating profitability with net income of $47.9 million. The company maintains a focused commercial strategy centered on its lead therapeutic asset, Korlym, which addresses a significant unmet medical need in the treatment of endogenous Cushing's syndrome. With operations headquartered in the San Francisco Bay Area, Corcept has established itself as a key player in the specialty pharmaceutical sector, delivering sustainable growth as evidenced by its 25% one-year stock price appreciation.
Source
Originally published at www.fool.com.